AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02184923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: presentation of visual vertical
Study NCT03018613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.
Study NCT03018613 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline and the traditional treatments for chronic functional constipation in part 2
Study NCT03148041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health education program
Description: Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used
Study NCT03148041 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: health education program
Description: Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used
Study NCT04974801 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Provox Life
Description: Use of Provox Life range of HMEs for different situations and their attachments (adhesives and laryngectomy tubes)
Study NCT04974801 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Usual Care
Description: Continued Usual Care routines.
Study NCT01156714 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treadmill training with aerobic exercise
Description: walk on treadmill for aerobic exercise
Study NCT02907359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Study NCT02907359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Choice
Description: * BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~* LDAC: 20 mg/m\^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~* Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m\^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m\^2/day) or idarubicin (9-12 mg/m\^2/day) or mitoxantrone (8-12 mg/m\^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice.
Study NCT03517527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT03492333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free diet
Description: Gluten-free diet- Instructions provided by a dietitian
Study NCT04601688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Ophthalmic and Intravitreal Dexamethasone
Description: Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
Study NCT04601688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Ophthalmic
Description: Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
Study NCT00919607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate extended-release
Description: 300mg,oral,single dose
Study NCT00690534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: variable rate for 3 hours
Study NCT00690534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mixed meal
Description: mixed meal
Study NCT00690534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed meal
Description: mixed meal
Study NCT00490113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxamine
Description: Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
Study NCT02637466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vortioxetine
Study NCT02637466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Study NCT04177862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Sufentanil
Description: 30 mcg of sublingual sufentanil
Study NCT04177862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Fentanyl
Description: 50 mcg of IV fentanyl
Study NCT04640168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
Study NCT04640168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.
Study NCT04640168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching oral baricitinib or intravenous dexamethasone.
Study NCT04640168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
Study NCT04435873 — intervention group
Intervention type: OTHER
Intervention: Survey using Your Home Dialysis Care Experience tool.
Description: Validation of a new survey instrument to capture the experience of care by home dialysis patients.
Study NCT04433208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complex oligosaccharide
Description: Complex oligosaccharide concentrate
Study NCT04433208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic
Study NCT01391065 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MR PET Guided Brachytherapy
Study NCT01545921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Of Life questionnaires completion
Description: Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D.
Study NCT01156714 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Memory training with computerized memory program
Description: memory testing and training on computer program
Study NCT02005302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1,25(OH)2 Vitamin D3
Description: Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
Study NCT02005302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
Study NCT01156714 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combination of treadmill training and computerized memory
Description: both exercise and cognitive computer training
Study NCT02005302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low protein diet
Description: Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
Study NCT02959359 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ledipasvir 90mg/Sofosbuvir 400 mg
Description: A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
Study NCT02959359 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
Study NCT00561288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 2 x 1000 mg doses per day
Study NCT00561288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cornstarch
Description: 2 x 1000 mg cornstarch per day
Study NCT01692977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Study NCT01692977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological assessment
Study NCT02784847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triheptanoin
Description: Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
Study NCT00673335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Study NCT00673335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06060795 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electro-conductance measurement
Description: Interventions are done to diagnose Autonomic Nervous system Troubles
Study NCT01390922 — intervention group
Intervention type: DRUG
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A
Study NCT00657982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10mg BID
Study NCT00786799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: Omega-3's are administered in the form of an orange pudding made by Coromega~1 mg of omega-3 fatty acid 2 times per day
Study NCT02005302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal protein diet
Description: Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
Study NCT04123938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea Protein
Description: Soluble pea protein
Study NCT02770534 — intervention group
Intervention type: PROCEDURE
Intervention: blood test
Description: 10mls extra mls of blood taken during usual phlebotomy procedures
Study NCT04123938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: Whey protein concentrate
Study NCT04123938 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Non-protein isocaloric comparator
Study NCT03037788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO3979
Description: Application of cream to each axilla
Study NCT03037788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO3970
Description: Application of cream to each axilla
Study NCT03037788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO3992
Description: Application of cream to each axilla
Study NCT03037788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (WO3988)
Description: Application of cream to each axilla
Study NCT03397290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) Imaging
Description: Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
Study NCT00131235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine treatment twice during pregnancy
Description: Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points.
Study NCT00131235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine at 4-week intervals
Description: Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.
Study NCT00131235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice
Description: Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.
Study NCT04282356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy during surgery
Description: During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection). They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8) with at least 3 courses performed (up to 4-6 allowed).
Study NCT01256710 — intervention group
Intervention type: DEVICE
Intervention: Trifecta™ aortic bioprosthesis
Description: Surgical aortic valve replacement with the Trifecta™ valve.
Study NCT03521453 — intervention group
Intervention type: OTHER
Intervention: PEPPER robot
Description: Presence of a Robot (PEPPER Robot), designed and programmed to give informations, using a screen and vocal. All the patients in the second period will have access to,the robot, while waiting for the visit.
Study NCT02500069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion of tap water in all regions (duodenum, jejunum and ileum)
Study NCT02500069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein (in duodenum)
Description: infusion of protein in duodenum
Study NCT02500069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein (in jejunum)
Description: infusion of protein in jejunum
Study NCT02500069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein (in ileum)
Description: infusion of protein in ileum
Study NCT05539235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: different degrees of adjustment of the injection interval
Description: Treatment was an intravitreal injection of 0.5 mg conbercept using modified T\&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks.
Study NCT00892164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: harmonic scalpel device (FOCUS)
Description: hemostatic device utilized intraoperatively
Study NCT00892164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrothermal bipolar vessel sealing system (LIGASURE PRECISE)
Description: hemostatic device utilized intraoperatively
Study NCT01573624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GSK573719
Description: 100/15.6
Study NCT01573624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GSK573719
Description: 100/31.25
Study NCT01573624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GSK573719
Description: 100/62.5
Study NCT01573624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GSK573719
Description: 100/125
Study NCT01573624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GSK573719
Description: 100/250
Study NCT01573624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF
Description: 100
Study NCT01573624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/VI
Description: 100/25
Study NCT04433208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPI
Description: Over-the-counter proton pump inhibitor (PPI)
Study NCT00999986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 50 mg oral per day for 7 days
Study NCT04249804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 1000 MG
Description: intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering
Study NCT00945022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wetting lips following surgery using anesthesia
Description: The investigator will position the Lipsus device in accordance with the instructions for use
Study NCT01624428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 mg bid varenicline titrated over a 2 week period
Study NCT01624428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg bid placebo titrated over a 2 week period
Study NCT02237846 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human umbilical cord tissue-derived mesenchymal stem cells
Study NCT01897675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage with packing (wick) placement
Study NCT01897675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abscess drainage with loop placement
Study NCT02722928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Ventilation with 100% oxygen
Description: Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
Study NCT01281748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous methylprednisolone
Description: methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
Study NCT01281748 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intravenous normal saline solution
Description: 50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
Study NCT02974985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injection of Restylane Lyft and Restylane L
Description: Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups
Study NCT02743572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron sucrose-1
Description: iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d
Study NCT02743572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron sucrose-2
Description: iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d
Study NCT02743572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron sucrose-3
Description: iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d
Study NCT02743572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron sucrose-4
Description: iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
Study NCT03066765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linguaflex Tongue Retractor
Description: Tongue implant
Study NCT01185327 — intervention group
Intervention type: BEHAVIORAL
Intervention: Breastfeeding
Description: Breastfeeding